Lyra Therapeutics (LYRA) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts LYRA Hot Sheet
Join SI Premium – FREE
Lyra Therapeutics (NASDAQ: LYRA) reported Q3 EPS of ($0.18), $0.04 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $195 thousand versus the consensus estimate of $315.6 thousand.
For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- loanDepot receives NYSE non-compliance notice over stock price
- Sigma Lithium resumes full operations after signing TAC agreement
- Real and RE/MAX Holdings receive court approval for merger
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
